

**RECORDABLE**PATENT  
PC7250A/MEBIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: : EXAMINER:  
DOUGLAS J.M. ALLEN ET AL. :  
CONTINUATION OF: :  
SERIAL NO.: 07/449,961 : ART UNIT:  
FILED: DECEMBER 21, 1992 :  
FOR: AZITHROMYCIN DIHYDRATE :

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

DECLARATION UNDER 37 C.F.R. § 1.132

I, Helen R. Hangac, declare that:

1. I received a Ph.D. degree in Analytical Chemistry from Duke University in 1982.

2. I have been employed by Pfizer Inc, assignee of the above-identified application, in the Analytical Research and Development Department at Groton, Connecticut since 1982. My current position is that of project leader in which I am responsible for analytical procedures performed on experimental pharmaceuticals, including azithromycin.

3. I am familiar with the subject matter of the above-identified application.

4. A series of experiments were performed under my direction by Near Infrared Spectroscopy and X-ray Powder Diffraction to determine if significant amounts of azithromycin dihydrate (Type A) were present in azithromycin (Type B) a hygroscopic monohydrate. The

COPY TO NEW YORK 12-21-92  
200-

-2-

1 have been shown to be equivalent using infrared spectrometry, and/or X-ray powder diffraction and are equivalent to the original sample described by Bright in U.S. Patent 4,474,768.


AZITHROMYCIN TYPE B LOTS EXAMINED/USED IN NEAR IR AND X-RAY STUDIES		
LOT NUMBER	TYPE	SOLVENT SYSTEM
1022107	TYPE B	ACETONE/CHLOROFORM
4351080	TYPE B	ACETONE/CHLOROFORM
1039117	TYPE B	ACETONE/CHLOROFORM
4101026	TYPE B	ETHANOL/WATER
13,577-209-1F	TYPE B	ETHANOL/WATER
4101036	TYPE B	ACETONE/CHLOROFORM
17,419-216-3	TYPE B	ACETONE
11,860-18-1 <sup>1</sup>	TYPE B	ETHANOL/WATER
<sup>1</sup> Sample referenced in Bright, U.S. Patent 4,474,768, Example 3.		

8. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

12/18/92

Date

Vega/Declaration.bhh



Helen H. Hangac